The UK s largest pharmaceutical company, Rafa, has announced a joint partnership with the British Pharmaceuticals and Drug Administration (FDA) to promote access to medicines for rare diseases in developing countries in the Middle East and Eastern Europe (CEE).
Source: prnewswire.comPublished on 2022-08-01
Related news
- Intesa Sanpaolo launches new startup development programme
- Rare Diseases How to Leverage Social Media for Patient Analysis
- Observing water - related events to support decision - making
- Advisers could ditch fact - finding under CDR
- Accenture Makes Strategic Investment in African Fintech Startup Okra
- A $88 Billion Global Opportunity for Healthcare Analytics by 2026 - New Research from StrategyR
- Informatica - Databricks Alliance Looks To Broaden Data Lakehouse Adoption
- Why has Da Nang taken the lead in digital transformation ?
- Mapping Major Milestones in the Evolution of North Korea Cyber Program The Diplomat
- Rafa Laboratories to acquire a significant stake in ExCEEd Orphan and expand its international capabilities in medicines addressing rare diseases
- Presentation to the National Space Council User Advisory Group by Thomas Zurbuchen
- French Railway Authority SNCF Rseau Bases Enterprise Common Data Environment on Trimble Collaboration Software
- Latin America could become a world leader in non - commercial open science
- DataSeers appoints Gracie Ortiz as OperationsSeer ( COO )
- Rafa Laboratories to acquire a significant stake in ExCEEd Orphan and expand its international capabilities in medicines addressing rare diseases